WO2008003702A2 - Quinazolines et composés hétérocycliques associés, et leur utilisation dans le domaine thérapeutique - Google Patents

Quinazolines et composés hétérocycliques associés, et leur utilisation dans le domaine thérapeutique Download PDF

Info

Publication number
WO2008003702A2
WO2008003702A2 PCT/EP2007/056689 EP2007056689W WO2008003702A2 WO 2008003702 A2 WO2008003702 A2 WO 2008003702A2 EP 2007056689 W EP2007056689 W EP 2007056689W WO 2008003702 A2 WO2008003702 A2 WO 2008003702A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound according
methylpiperazinyl
phenyl
aryl
Prior art date
Application number
PCT/EP2007/056689
Other languages
English (en)
Other versions
WO2008003702A3 (fr
Inventor
Rogier Adriaan Smits
Herman Dirnawan Van Lim
Regorius Leurs
Iwan Jozef Philomena De Esch
Original Assignee
Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg filed Critical Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg
Priority to AU2007271187A priority Critical patent/AU2007271187A1/en
Priority to JP2009517257A priority patent/JP2009541460A/ja
Priority to EP07787012A priority patent/EP2044027A2/fr
Priority to CA002657702A priority patent/CA2657702A1/fr
Priority to US12/307,197 priority patent/US20100016293A1/en
Publication of WO2008003702A2 publication Critical patent/WO2008003702A2/fr
Publication of WO2008003702A3 publication Critical patent/WO2008003702A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Definitions

  • the present invention relates to quinazolines and related heterocyclic compounds, and their therapeutic use. More particularly, it relates to compounds that interact with the histamine H 4 receptor, and to histamine H 4 receptor antagonists, and their use for treating, reducing or preventing disorders and discomforts mediated by the histamine H 4 receptor.
  • Histamine is important in human physiology because it is one of the chemicals released from certain cells (particularly mast cells) upon tissue injury or during the neutralisation of foreign material (e.g. antigens) by certain types of antibodies. Released histamine tends to dilate blood capillaries, often causing the skin to appear red and feel warm, and makes the capillaries more permeable, allowing fluid to escape into the surrounding tissue.
  • the biological activity of histamine is closely related with allergic responses and its deleterious effects, such as inflammation.
  • Events that induce the inflammatory response include physical stimulation (including trauma), chemical stimulation, infection, and invasion by microorganisms.
  • the inflammatory response is characterised by pain, increased temperature, redness, swelling, reduced function, itch, or any combination of these.
  • Mast cell degranulation releases histamine and leads to an inflammatory response.
  • immunological stimuli and non- immunological stimuli may cause the activation, recruitment and degranulation of mast cells.
  • the activation of mast cells initiates allergic inflammatory responses, which in turn cause the recruitment of other effector cells that further contribute to the inflammatory response.
  • the numerous functions that are exerted by histamine are mediated through at least four pharmacologically distinct receptors, which are all members of the G-protein-coupled receptor family.
  • the H 1 receptor is expressed in the brain, endothelial cells, and smooth muscle cells. Many of its functions contribute to allergic responses, and Hi receptor antagonists have been very successful drugs for the treatment of allergies.
  • the H 2 receptor has been demonstrated to function as a key modulator for gastric acid secretion, and H 2 receptor antagonists are widely used for the treatment of gastrointestinal ulcers.
  • the H 3 receptor is predominantly expressed in the human central nervous system.
  • histamine receptors couple to different signalling pathways via different G-proteins.
  • the histamine H 4 receptor is a seven-transmembrane, G-protein- coupled receptor with approximately 40% homology to the histamine H 3 receptor. However, in contrast to the H 3 receptor, the H 4 receptor is expressed at greater levels in e.g. mast cells, eosinophils and a variety of other cells of the immune system.
  • histamine H 4 receptor antagonist inhibits histamine H 4 receptor-mediated calcium influx and chemotaxis of mast cells (Thurmond et al., J. Pharmacol. Exp. Ther. 2004, 309(1), 404-413) and eosinophils (Raible et al., Am. J. Respir. CrIt. Care Med. 1994, 149(6), 1506-1511).
  • histamine H 4 is associated with cancer and itch. See J. K. Bell et al., Br. J. Pharmacol. 2004, 142 ⁇ 2), 374-380; and F. Cianchi et al., Clin. Cancer Res. 2005, 77, 6807-6815.
  • Q is CR 1 or N
  • X is CR 2 or N, provided that Q and X are not both N; Y is CR 3 or N; Z is CH or N; R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently H, F, Cl, Br, I, or a hydrocarbon radical which optionally contains one or more heteroatoms; and
  • R 7 is a heterocyclic group including one or more N atoms or a pharmaceutically acceptable salt, ester or solvate thereof.
  • compounds of formula (I) can be used to treat, reduce or prevent disorders and discomforts mediated by the histamine H 4 receptor.
  • they may be administered to a subject, e.g. as a pharmaceutical composition, in a therapeutically effective amount.
  • R 1 and R 2 are independently selected from H, F, Cl, Br, I, C 1-4 alkyl, C 2 5 alkenyl, C 1-4 alkoxy, cycloalkyl, aryl
  • phenyl such as phenyl
  • heteroaryl such as phenyl
  • -Ci- 4 alkyl-aryl such as benzyl or phenethyl
  • -Ci- 4 alkyl-heteroaryl such as heteroarylethyl
  • O-aryl such as O-phenylaryl
  • O- heteroaryl NH-aryl such as NH-phenyl, N H -heteroaryl
  • S-aryl such as S- phenyl
  • S-heteroaryl 0-C 1-4 alkyl-aryl such as O-CH 2 -phenyl, O-(CH 2 ) 2 -phenyl or O-(CH 2 ) 4 -phenyl, O-Ci- 4 alkyl-heteroaryl such as O-(CH 2 ) 2 -heteroaryl or O-
  • R 3 , R 4 , R 5 and R 6 are independently selected from H, F, Cl, Br, I, C-t- 4 alkyl, C 2 5 alkenyl, C 2 - 5 alkynyi, Ci -4 alkoxy, Ci -4 alkylthio, C 3-6 cycloalkyl, 0-C 3-6 cycloalkyl, phenyl, benzyl, O-phenyl, NH-phenyl, S-phenyl, O- C 1-4 alkyl-phenyl such as O-(CH 2 ) 2 -phenyl or O-(CH 2 ) 4 -phenyl, C 1-4 alkyl-aryl such as CH 2 CH 2 -phenyl, CF 3 , 0-CF 3 , S-CF 3 , hydroxy, nitro, cyano, O-C 1 .
  • R a and R b is independently selected from H, C 1-4 alkyl, phenyl, benzyl and phenethyl, and wherein any phenyl, alkyl or cycloalkyl moiety is optionally substituted with 1 to 3 substituents selected from C 1 .3 alkyl, halogen, hydroxy, amino and C 1 - 3 alkoxy.
  • R 7 is a heterocyclic radical comprising one or more N atoms. It is bonded to the bicyclic nucleus via a N or C atom, bonding via N being preferred.
  • This radical may be mono- or bi-cyclic, and optionally carries substituents, e.g. substituents as defined above.
  • R 7 is selected from 4-7 membered heterocyclyl, C 3-7 cycloalkyl-4-7 membered heterocyclyl and bis-(4-7 membered heterocyclyl).
  • R 7 is selected from cyclic amines, spiroamines and bridged cycloamines.
  • R 7 may in particular be selected from any of the following groups
  • n 1 or 2;
  • R 8 and R 9 are independently H or C1-3 alkyl
  • R 10 is H, C 3 . 5 alkenyl with no sp 2 -carbon member attached directly to the Reattached nitrogen member, C 3-5 alkynyl with no sp-carbon member attached directly to the Reattached nitrogen member, CH 2 CH 2 OH, Ci- 4 alkyl-O-Ci-4 alkyl or Ci- 6 alkyl which is optionally substituted by halogen, cyano, hydroxy, carboxy, amino, C 1-6 alkylamino, N,N-di(C 1-6 alkyl)amino, Ci -6 alkylthio, C 1-6 alkoxy or C 3-8 cycloalkyl; alternatively R 10 may be taken together with R 9 , wherein the Reattached carbon member, and the Reattached nitrogen member form a 5-, 6-, or 7- membered heterocyclic ring, wherein said ring has 0 or 1 additional heteroatoms selected from O, S, NH and NCi -6 alkyl, and wherein said heterocycl
  • R 12 , R 13 , R 14 and R 15 are independently hydrogen or Ci -6 alkyl optionally substituted by halogen, cyano, hydroxy, carboxy, amino, C 1-6 alkylamino, N-(Ci -6 alkyl)amino, N,N-di(Ci -6 alkyl)amino, Ci- 6 alkylthio, Ci -6 alkoxy, or C 3-8 cycloalkyl.
  • R is H or any substituent, e.g. methyl or ethyl, and the curved lines represent the bond of the amine group with the heterocyclic scaffold.
  • Amines 5 and 6 are examples of spiroamines.
  • Amines 7, 8, 9 and 10 are examples of compounds that have stereoisomers, of which all forms (e.g. S- and R-isomers) are included.
  • R 7 may also be linked to the bicyclic nucleus via a C atom. Examples of such groups are 7-octahydroindolizinyl and 1-methyl-4- piperidinyl.
  • alkyl as used herein includes straight-chain and branched hydrocarbon groups.
  • alkenyl as used herein includes straight-chain and branched hydrocarbon groups as above with at least one carbon-carbon double bond (sp 2 ).
  • alkynyl as used herein includes straight-chain and branched hydrocarbon groups as above with at least one carbon-carbon triple bond (sp). Hydrocarbons having a mixture of double bonds and triple bonds are grouped as alkynyls herein.
  • alkoxy as used herein includes straight-chain and branched alkyl groups with a terminal oxygen linking the alkyl group to the rest of the molecule.
  • aryl as used herein includes any functional group or substituent comprising an aromatic ring.
  • the aryl may be selected from moieties comprising a phenyl, naphtyl or biphenyl.
  • the aryl may comprise one or more heteroatoms, in which case the aryl may be referred to as "heteroaryl".
  • Preferred examples of heteroaryl groups include pyridine, furane, thiophene, triazole and tetrazole.
  • Any hydrocarbon radical may be, for example, a C 1-2O hydrocarbon, preferably a C1.12 hydrocarbon, and more preferably a d. 10 hydrocarbon. This range applies also to other groups, including heterocyclic groups, and also as a preference.
  • substitutions and combinations of substitutions recited herein refer to substitutions that are consistent with the valency of the member being substituted.
  • the "pharmaceutically acceptable salt, ester or solvate thereof” refers to those salts, ester forms and solvates of the compounds of the present invention that would be apparent to the pharmaceutical chemist, i.e. those that are nontoxic and that would favourably affect the pharmacological properties of said compounds of the present invention.
  • Those compounds having favourable pharmacological properties would be apparent to the pharmaceutical chemist, i.e. those that are non-toxic and that possess such pharmacological properties to provide sufficient palatability, absorption, distribution, metabolism and excretion.
  • Other factors, more practical in nature, that are important in the selection are cost of raw materials, ease of crystallisation, yield, stability, hygroscopicity, and flowability of the resulting bulk drug.
  • Representative bases that may be used in the preparation of pharmaceutically acceptable salts include the following: ammonia, L-arginine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylenediamine, N- methyl-glucamine, hydrabamine, 1 H-imidazole, L-lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1-(2- hydroxyethyl)-pyrrolidine, secondary amine, sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide.
  • esters examples include Ci -7 alkyl, C 5-7 cycloalkyl, phenyl, substituted phenyl, and phenyl-Ci- 6 alkyl esters.
  • Preferred esters include methyl esters. If R 7 is the group of formula (II), n is preferably 1. In a preferred embodiment, R 8 and R 9 are hydrogen atoms, while R 10 is a methyl group.
  • R 7 is the group of formula (III)
  • a preferred class of compounds according to the invention is quinoxaline compounds of general formula (I), wherein Q is CR 1 , X is N, Y is CR 3 , and Z is
  • Particularly preferred compounds are those quinoxalines wherein at least three groups out of R 3 , R 4 , R 5 and R 6 are hydrogen atoms. Further preferred compounds are those quinoxalines wherein R 7 is 4-methylpiperazino.
  • Particularly preferred compounds are those quinazolines wherein at least three groups out of R 3 , R 4 , R 5 and R 6 are hydrogen atoms.
  • Further preferred compounds are those quinazolines wherein R 7 is 4-methylpiperazino.
  • a further preferred class of compounds is quinoline compounds of general formula (I), wherein Q is CR 1 , X is CR 2 , Y is CR 3 , and Z is N.
  • Particularly preferred compounds are those quinolines wherein R 1 , R 2 , R 3 , R 5 and R 6 are hydrogen atoms. It is further preferred that R 7 is 4-methylpiperazino.
  • Yet another preferred class of compounds is isoquinoline compounds of general formula (I), wherein Q is N, X is CR 2 , Y is CR 3 , and Z is CH.
  • Particularly preferred compounds are isoquinolines wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are hydrogen atoms.
  • Further preferred compounds are those isoquinolines wherein R 7 is 4-methylpiperazino. Tables 1 -5 illustrate compounds of the invention.
  • the present invention includes prodrugs of the compounds of the invention.
  • such prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the bio-active compound.
  • the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound that may not be specifically disclosed, but that converts to the specified compound in vivo after administration to the patient.
  • the term "compound”, when applied to compounds of this invention shall encompass any specific compound according to the present invention or any compound (or prodrug) that converts to the specifically disclosed compound in vivo after administration, even if such prodrug is not explicitly disclosed herein.
  • Compounds of the present invention are antagonists, inverse agonists or partial agonists of histamine H 4 receptors. Thus, these compounds reversibly or irreversibly bind to the histamine H 4 receptor. Without wishing to be bound by theory, this is considered to be indicative of therapeutic utility.
  • an antagonist may also be obtained by an inverse agonist or a partial agonist.
  • Inverse agonism describes the property of a compound to actively turn off a receptor that displays constitutive activity.
  • Constitutive activity can be identified in cells that have been forced to over-express the human H 4 receptor.
  • Constitutive activity can be measured by measuring cAMP (cyclic adenosine monophosphate) levels or by measuring a reporter gene sensitive to cAMP levels after a treatment with a cAMP stimulating agent such as forskolin.
  • cAMP cyclic adenosine monophosphate
  • a reporter gene sensitive to cAMP levels after a treatment with a cAMP stimulating agent such as forskolin.
  • Cells that over-express H 4 receptors will display lower cAMP levels after forskolin treatment than non-expressing cells.
  • Compounds that behave as H 4 agonists will dose-dependently lower forskolin-stimulated cAMP levels in H 4 - expressing cells. Compounds that behave as H 4 inverse agonists will dose- dependently stimulate cAMP levels in H 4 -expressing cells. Compounds that behave as H 4 antagonists will block either H 4 agonist induced inhibition of cAMP or H 4 inverse agonist induced increases in cAMP.
  • Compounds of the invention may be administered to a subject, in therapy, e.g. for the treatment of inflammation.
  • Inflammation herein refers to the response that develops as a consequence of release of inflammatory mediators, such as histamine, serotonin, leukotrienes, prostaglandins, cytokines, chemokines, which in turn is caused by at least one stimulus, which can be for example an immunological stimulus or a non-immunological stimulus.
  • inflammatory mediators such as histamine, serotonin, leukotrienes, prostaglandins, cytokines, chemokines
  • subject as used in this application includes animals and in particular mammals including and preferably being a human, a dog, a cat, a horse, a rat, a rabbit, a mouse, and a non-human primate, which animal is in need of observation, experiment, treatment or prevention in connection with the relevant disease or condition.
  • composition includes a product comprising the specified ingredients in the specified amounts, including in the therapeutically effective amounts, as well as any product that results directly or indirectly from combinations of the specified ingredients in the specified amounts.
  • terapéuticaally effective amount as used in this description and the appending claims is meant to be that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • the compounds of the invention are useful for the amelioration of symptoms associated with the treatment and/or the prevention of conditions and diseases such as inflammatory disorders, allergic disorders, dermatological disorders, autoimmune disease, lymphatic disorders, immunodeficiency disorders and cancer, including the more specific conditions and diseases given above.
  • the invention is also directed to a pharmaceutical composition for treating or preventing an H 4 receptor-mediated condition in a subject, comprising a therapeutically effective amount for treating, reducing or preventing an H 4 receptor-mediated condition of at least one H 4 receptor antagonist or partial agonist or inverse agonist according to the present invention.
  • Such pharmaceutical compositions typically also comprise a pharmaceutically acceptable carrier.
  • the invention features an anti-inflammatory composition, comprising a therapeutically effective amount for treating or preventing inflammation of at least one anti-inflammatory compound according to the present invention.
  • compositions typically also comprise a pharmaceutically acceptable carrier.
  • Another example of the invention is the use of a compound according to the present invention in the preparation of a medicament for treating any one of the conditions referred to herein; one of such conditions is inflammation.
  • Another example of the invention is the use of a compound according to the present invention in the treatment or prevention of any one of the conditions referred to herein; one of such conditions is inflammation.
  • the invention is also directed to a method for treating or preventing inflammation in a subject, comprising administering to a subject in connection with an inflammatory response a pharmaceutical composition that comprises a therapeutically effective amount of at least one anti-inflammatory compound according to the present invention.
  • the invention also features methods for treating or preventing an H 4 receptor-mediated condition in a subject, comprising administering to the subject a pharmaceutical composition that comprises a therapeutically effective amount of at least one H 4 receptor antagonist, partial agonist or inverse agonist according to the present invention.
  • Embodiments of methods for treating or preventing inflammation in a subject that comprise administering to the subject in connection with an inflammatory response a pharmaceutical composition comprising a therapeutically effective amount of at least one anti-inflammatory compound according to the present invention include methods wherein at least one of the following is satisfied: said inflammatory response is a response to a physical stimulus; said inflammatory response is a response to a chemical stimulus; said inflammatory response is a response to infection; said inflammatory response is a response to an invasion by a body that is foreign to said subject; said inflammatory response is a response to an immunological stimulus; said inflammatory response is a response to a non-immunological stimulus; said inflammatory response is a response to at least one of the conditions: allergy, asthma, chronic obstructed pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and more specifically wherein said inflammatory bowel disease is at least one of Crohn's disease and ulcerative colitis, psoriasis, allergic
  • the compounds of the invention can be used in the treatment of or therapy against cancer.
  • the compounds of the invention can be used to reduce, suppress or avoid itch.
  • Administration "in connection with" an inflammatory response according to the present invention includes administration at a time that it is at least one of prior to, at the onset of, and after inflammation is detected.
  • aspects of the invention include (a) a pharmaceutical composition comprising at least one compound according to the invention and a pharmaceutically acceptable carrier; (b) a packaged drug comprising (1) a pharmaceutical composition comprising at least a compound according to the present invention and a pharmaceutically acceptable carrier, and (2) instructions for the administration of said composition for the treatment or prevention of any one of the conditions referred to herein, such as an H 4 -mediated disease or condition, and more particularly inflammation.
  • This invention provides methods for treating, reducing or preventing an H 4 -mediated condition in a subject, said methods comprising administering to the subject a pharmaceutically effective amount of a composition comprising at least one compound according to the invention.
  • the action of the H 4 receptor is involved.
  • the invention features a method for treating an H 4 mediated condition in a subject, said method comprising administering to the subject a pharmaceutically effective H 4 -antagonising amount of a composition comprising at least one compound according to the invention.
  • treating a disorder means eliminating, reducing or otherwise ameliorating the cause and/or effects thereof. Terms such as to "inhibit" the onset of a disorder or event, and to "prevent” a disorder or condition mean preventing, delaying or reducing the likelihood of such onset.
  • unit dose is used herein to refer to physically discrete units suitable as unitary dosages for subjects, each unit containing a predetermined effective, pharmacologic effective amount of the active ingredient calculated to produce the desired pharmacological effect.
  • the specifications for the novel unit dosage forms of this invention are determined by, and are directly dependent on, the characteristics of the active ingredient, and on the limitations inherent in the art of compounding such an active ingredient for therapeutic use in subjects.
  • the pharmaceutical compositions can be prepared using conventional pharmaceutical excipients and compounding techniques.
  • suitable unit dosage forms are tables, capsules, pills, powders, powder packets, granules, wafers, and the like, segregated multiples of any unit dosage form, as well as liquid solutions, and suspensions.
  • Some liquid forms are aqueous, whereas other embodiments of liquid forms are non-aqueous.
  • Oral dosage forms may be elixirs, syrups, capsules, tablets and the like.
  • solid carriers examples include those materials usually employed in the manufacture of pills or tablets, such as lactose, starch, glucose, methylcellulose, magnesium stearate, dicalcium phosphate, mannitol and the like, thickeners such as tragacanth and methylcellulose USP, finely divided SiO 2 , polyvinylpyrrolidone, magnesium stearate, and the like.
  • Typical liquid oral excipients include ethanol, glycerol, water and the like.
  • excipients may be mixed as needed with diluents (for example, sodium and calcium carbonates, sodium and calcium phosphates, and lactose), disintegrants (for example, cornstarch and alginic acid), granulating agents, lubricants (for example magnesium stearate, stearic acid, and talc), binders (for example starch and gelatine), thickeners (for example paraffin, waxes, and petrolatum), flavouring agents, colouring agents, preservatives, and the like by conventional techniques known to those of ordinary skill in the art of preparing dosage forms.
  • Coatings can be present and include for example glyceryl monostearate and/or glyceryl distearate.
  • Capsules for oral use include hard gelatine capsules in which the active ingredient is mixed with a solid diluent, and soft gelatine capsules, in which the active ingredient is mixed, with water or an oil, such as peanut oil, liquid paraffin, or olive oil.
  • Parenteral dosage forms may be prepared using water or another sterile carrier. Parenteral solutions can be packaged in containers adapted for subdivision into individual doses. For intramuscular, intraperitoneal, subcutaneous, and intravenous use, the compounds according to the invention will be generally provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone, and gum tragacanth, and a wetting agent, such as lecithin.
  • suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone, and gum tragacanth, and a wetting agent, such as lecithin.
  • Suitable preservatives for aqueous suspensions include ethyl and n-propyl p- hydroxybenzoate.
  • Parenteral formulations include pharmaceutically acceptable aqueous or non-aqueous solutions, dispersions, suspensions, emulsions, and sterile powders for the preparation thereof.
  • carriers include water, ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained by the use of a coating such as lecithin, a surfactant, or maintaining appropriate particle size.
  • Carriers for solid dosage forms include (a) fillers or extenders, (b) binders, (c) humectants, (d) disintegrating agents, (e) solution retarders, (f) absorption accelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and (j) propellants.
  • Compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents; antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid; isotonic agents such as sugar or sodium chloride; absorption-prolonging agents such as aluminium monostearate and gelatine; and absorption-enhancing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispensing agents
  • antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid
  • isotonic agents such as sugar or sodium chloride
  • absorption-prolonging agents such as aluminium monostearate and gelatine
  • absorption-enhancing agents such as aluminium monostearate and gelatine.
  • Physiologically acceptable carriers are well known in the art.
  • liquid carriers are solutions in which compounds according to the invention form solutions, emulsions, and dispersions.
  • Compatible antioxidants such as methylparaben and propylparaben, can be present in solid and/or liquid compositions, as can sweeteners.
  • compositions according to the invention may include suitable emulsifiers typically used in emulsion compositions.
  • Gelling agents may also be added to compositions according to this invention.
  • Polyacrylic acid derivatives, such as carbomers are examples of gelling agents, and more particularly, various types of carbopol.
  • Suspensions may be prepared as a cream, an ointment, including a water-free ointment, a water-in-oil emulsion, an oil-in-water emulsion, and emulsion gel, or a gel.
  • Compounds according to the present invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, rectal, intracisternal, intravaginal, intravesical, topical or local administration, and by inhalation (bucal or nasal, preferably in the form of a spray).
  • oral administration the compounds according to the invention will be generally provided in the form of tablets, capsules, or as a solution or suspension.
  • Other methods of administration include controlled release formulations, such as subcutaneous implants and dermal patches.
  • compositions according to the invention may be ascertained by conventional methods.
  • the specific dosage level required for any particular subject will depend on a number of factors, including severity of the condition, type of symptoms needing treatment, the route of administration, the weight, age, and general condition of the subject, and the administration of other medicaments.
  • the daily dose (whether administered as a single dose or as divided doses) will be in the range of from about 0.01 mg to about 1000 mg per day, more usually from about 1 mg to about 500 mg per day, and most usually from about 10 mg to about 200 mg per day.
  • a typical dose will be expected to be between about 0.0001 mg/kg and about 15 mg/kg, especially between about 0.01 mg/kg and about 7 mg/kg, and most especially between about 0.15 mg/kg and 2.5 mg/kg.
  • Oral dose ranges include from about 0.01 to 500 mg/kg, daily, more preferably from about 0.05 to about 100 mg/kg, taken in 1-4 separate doses. Some compounds of the invention may be orally dosed in the range of about 0.05 to about 50 mg/kg daily, while others may be dosed at 0.05 to about 20 mg/kg daily. Infusion doses can range from about 1.0 to about 1.0 x 10 4 ⁇ g/(kg min) of inhibitor, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days. For topical administration, compounds of the present invention may be mixed with a pharmaceutical carrier at a concentration from about 0.1 to about 10% of drug to vehicle.
  • Capsules, tablets or other formulations may be of between 0.5 and 200 mg, such as 1 , 3, 5, 10, 15, 25, 35, 50 mg, 60 mg, and 100 mg and can be administered according to the disclosed methods.
  • Daily dosages are envisaged to be, for example between 10 mg and 5000 mg for an adult human subject of normal weight.
  • the compounds of the invention can be prepared according to processes within the skill of the art and/or according to processes of this invention, such as those described in the schemes and examples that follow and by matrix or combinatorial methods.
  • Flash column chromatography was typically carried out on an Argonaut Flashmaster 1M Il flash chromatography system, using prepacked lsolute Flash Si Il columns with the UV detector operating at 254 nm. All meltingpoints are uncorrected and were measured on an Optimelt Automated Melting Point System from Stanford research systems. All 1 H NMR and 13 C NMR spectra were measured on a Br ⁇ ker 200.
  • Analytical HPLC-MS analyses were conducted using a Shimadzu LC-8A preparative liquid chromatograph pump system with a Shimadzu SPD-10AV UV- VIS detector with the MS detection performed with a Shimadzu LCMS-2010 liquid chromatograph mass spectrometer.
  • Preparative HPLC-MS separations were carried out on an Agilent 1100 Series preparative HPLC-MS System including a G1968D active splitter, G1315B DAD and a G1946D LC/MSD using an ESI ion source.
  • 2,4,6-Trichloroquinazoline can be prepared according to a procedure described in the scientific literature (J. Med. Chem. 1995 p. 3547-3557). This procedure can also be used for the synthesis of 2,4,7-trichloroquinazoline, another precursor of compounds of the invention.
  • Example 1 4-Ammo-6-chloro-2-(4-methylpiperazinyl)quinazoline (VUF10247)
  • 2,4,6-Trichloroquinazoline 300 mg was added to a saturated solution of ammonia in MeOH (5.0 mL) and stirred at room temperature (r.t.). After 16 hours the mixture was diluted with EtOAc (50 mL) and washed with water and brine. After drying over Na 2 SO 4 the organic phase was concentrated (about 3 mL) and transferred to a microwave tube containing ⁇ /-methylpiperazine (1.0 mL). The mixture was heated at 140 0 C for 5 minutes using microwave irradiation. The formed suspension was then diluted with EtOAc and washed with water and brine.
  • 2,6-Dichloroquinoline 300 mg was added to ⁇ /-methylpiperazine (2.0 ml_) and was heated in the microwave at 160 9 C for 5 min. After completion the obtained solution was evaporated to dryness, the residue was dissolved in EtOAc and then washed with saturated NaHCO 3 solution. The organic layer was dried with brine and Na 2 SO 4 . The product was recrystallised from EtOAc/Et 2 O.
  • a microwave tube was charged with 500 mg of 3- trifluoromethylsulphonate-isoquinoline (500 mg) and ⁇ /-methylpiperazine (1.5 mL). The tube was heated at 160 0 C for 5 minutes and the obtained product was partitioned between CHCI 3 and water. Extraction of the aqueous layer and drying over Na 2 SO 4 , followed by evaporation of the solvent yielded the crude product. Purification over SiO 2 (EtOAc) yielded 264 mg (64%) of title compound.
  • Example 12 3-Benzyl-2-(4-methylpiperazinyl)-quinoxaline (VUF10148) A microwave tube charged with 3-benzyl-2-chloroquinoxaline (400 mg) and ⁇ /-methylpiperazine (3.0 ml_) was heated at 120 0 C for 5 minutes. Then water (25 mL) was added and the aqueous layer was extracted with EtOAc. The combined organic extracts were dried with brine and Na 2 SO 4 . Evaporation of the organic solvents and subsequent purification over SiO 2 (EtOAc 90%, Et 3 N 5%, MeOH 5%) yielded 446 mg (89%) of product.
  • Example 13 6,7-Dichloro-2-methoxy-3-(4-methylpiperazinyl)-quinoxaline (VUF10325) 2,3,6-Trichloro-3-(4-methylpiperazinyl)-quinoxaline (200 g) and a 5.4 M solution of NaOMe in MeOH (0.14 mL) were dissolved in MeOH (10 mL) and heated at reflux. After 2 hours the solution was diluted with CH 2 CI 2 and washed with water and brine. The organic layer was dried over Na 2 SO 4 and evaporated to yield 199 mg (99%) of product.
  • Example 16 provides a general synthesis of 2,4- disubstituted quinazolines (General Method A).
  • 2,4,6-Trichloroquinazoline 300 mg was dissolved in THF (5.0 ml) after which a solution of methylamine in water (0.12 ml, 40% w/w) was added to the solution. After 2 hours, the formed suspension was diluted with EtOAc (50 ml) and washed with water and brine. The organic phase was dried over Na 2 SO 4 and concentrated (about 3 ml) after which it was transferred to a microwave tube containing ⁇ /-methylpiperazine (1.0 ml) and EtOAc (3.0 ml). The mixture was heated at 14O 0 C for 5 minutes with microwave irradiation. The product was then diluted with EtOAc and washed with water and brine.
  • Example 29 provides a general synthesis of 2,4- diamino-substituted quinazolines (General Method B).
  • Boc-protected intermediates (for VUF10438 and VUF10440) were deprotected in 4 M of HCI in dioxane until LCMS indicated complete conversion to the final unprotected product. All final compounds were analyzed with LCMS under condition //.
  • HEK 293T cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 IU/ml penicillin, and 50 ⁇ g/ml streptomycin in 5% CO2 humidified atmosphere at 37 ° C. Approximately 4 million cells were seeded in a 10-cm dish and cultured overnight before transfection. For transfection of each dish of cells, the transfection mixture was prepared in 1 ml serum-free DMEM and contained 5 ⁇ g of human H 4 R receptor plasmid and 15 ⁇ l of 1 mg/ml 25 kDa linear polyethyleneimine (Polyscience, Inc., USA).
  • DMEM Dulbecco's modified Eagle medium
  • FBS fetal bovine serum
  • streptomycin 50 ⁇ g/ml streptomycin
  • the membranes were typically incubated with 10 '4 to 10 "11 M of ligands (stock concentration was 10 mM 1 DMSO) in the presence of [ 3 H]histamine (Perkin-Elmer Life Science, Inc., USA) in a total volume of 200 ⁇ l.
  • the reaction mixtures were incubated for 1 hour at room temperature (22°C), and harvested on 96-well glass fiber C plates that were pretreated with 0.3% 750 kDa PEI.
  • the binding assay data were analyzed using Prism 4.0 (Graphpad Software Inc., USA).
  • CHO Chonese Hamster Ovary
  • Binding analysis was performed using crude cell homogenates of CHO cells, stably transfected with a synthetic gene encoding the human histamine H 4 receptor (GENEart Gmbh, Regensburg, Germany), in 50 mM Tris-HCI buffer pH 7.4 and approximately 7 nM [ 3 H]histamine (18.1 Ci/mmoi, Perkin-Elmer), with or without competing ligands in a total volume of 200 ⁇ l_ as essentially described by Um et al., J. Pharmacol. Exp. Ther. 2005, 314, 1310-1321.
  • Bound radioligand was collected on 0.3% polyethyleneimine-pretreated 96-well GF/C plates, and washed three times with 0.3 ml_ of ice-cold washing buffer containing 50 mM Tris-HCI (pH 7.4 at 4 0 C).
  • HEK 293T cells were transiently transfected with H 4 receptor cDNA and a CRE- ⁇ -galactosidase reporter plasmid (pCRE/ ⁇ -gal, Chen et al., 1995) using polyethyleneimine. After 48 hours, the cells were exposed for six hours to putative H 4 receptor ligands in the absence or presence of histamine in serum-free DMEM (Dulbecco's Modified Eagle's Medium) medium containing 1 ⁇ M forskolin. Thereafter the beta-galactosidase activity was determined as essentially described by Lim et al., J. Pharmacol. Exp. Ther. 2005, 314, 1310-1321 , and known to those skilled in the art.
  • DMEM Dens Modified Eagle's Medium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)

Abstract

L'invention concerne des composés qui interagissent avec le récepteur d'histamine H4 et peuvent être utiles pour le traitement ou la prévention de troubles et d'états induits par le récepteur de l'histamine H4, p. ex. l'inflammation. Les composés selon l'invention sont représentés par la formule (I) dans laquelle Q représente CR1 ou N; X représente CR2 ou N, à condition que Q et X ne représentent pas tous les deux N; Y représente CR3 ou N; Z représente CH ou N; R1, R2, R3, R4, R5 et R6 sont indépendamment H, F, Cl, Br, I ou un groupement hydrocarboné contenant éventuellement un ou plusieurs hétéroatomes; et R7 représente un radical hétérocyclique comprenant un ou plusieurs atomes N; ou un de leurs sels, esters ou solvates pharmaceutiquement acceptables.
PCT/EP2007/056689 2006-07-03 2007-07-03 Quinazolines et composés hétérocycliques associés, et leur utilisation dans le domaine thérapeutique WO2008003702A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2007271187A AU2007271187A1 (en) 2006-07-03 2007-07-03 Fused bicyclic compounds interacting with the histamine H4 receptor
JP2009517257A JP2009541460A (ja) 2006-07-03 2007-07-03 ヒスタミンｈ４受容体と相互作用する縮合二環式化合物
EP07787012A EP2044027A2 (fr) 2006-07-03 2007-07-03 Composés bicycliques fusionnés interagissant avec le récepteur histamine h4
CA002657702A CA2657702A1 (fr) 2006-07-03 2007-07-03 Quinazolines et composes heterocycliques apparentes et utilisation therapeutique connexe
US12/307,197 US20100016293A1 (en) 2006-07-03 2007-07-03 Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06076352 2006-07-03
EP06076352.1 2006-07-03

Publications (2)

Publication Number Publication Date
WO2008003702A2 true WO2008003702A2 (fr) 2008-01-10
WO2008003702A3 WO2008003702A3 (fr) 2008-04-10

Family

ID=37441537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/056689 WO2008003702A2 (fr) 2006-07-03 2007-07-03 Quinazolines et composés hétérocycliques associés, et leur utilisation dans le domaine thérapeutique

Country Status (6)

Country Link
US (1) US20100016293A1 (fr)
EP (1) EP2044027A2 (fr)
JP (1) JP2009541460A (fr)
AU (1) AU2007271187A1 (fr)
CA (1) CA2657702A1 (fr)
WO (1) WO2008003702A2 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077263A1 (fr) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines et composés hétérocycliques rélatifs et leur utilisation thérapeutique
WO2009134726A1 (fr) * 2008-04-28 2009-11-05 Abbott Laboratories Dérivés de pyrimidine substitués comme ligands des récepteurs à l’histamine h4
EP2201982A1 (fr) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur H4 de l'histamine pour le traitement de troubles vestibulaires
WO2011112766A2 (fr) 2010-03-10 2011-09-15 Kalypsys, Inc. Inhibiteurs hétérocycliques de récepteurs de l'histamine destinés au traitement de maladie
WO2011135376A1 (fr) 2010-04-30 2011-11-03 Astex Therapeutics Limited Inhibiteurs de pyrazolyl-quinazoline kinase
US8063215B2 (en) 2007-08-22 2011-11-22 Astrazeneca Ab Cyclopropyl amide derivatives
WO2013061081A1 (fr) 2011-10-28 2013-05-02 Astex Therapeutics Limited Benzopyrazines anticancéreuses par le biais de l'inhibition de fgfr kinases
WO2013061080A1 (fr) 2011-10-28 2013-05-02 Astex Therapeutics Limited Pyridopyrazines anti-cancéreuses par l'inhibition de kinases de fgfr
WO2013061074A1 (fr) 2011-10-28 2013-05-02 Astex Therapeutics Limited Quinolines comme modulateurs de la fgfr kinase
WO2013061077A1 (fr) 2011-10-28 2013-05-02 Astex Therapeutics Limited Nouveaux composés
US8575184B2 (en) 2009-09-03 2013-11-05 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
WO2013182711A1 (fr) 2012-06-08 2013-12-12 Sensorion Inhibiteurs des récepteurs h4 pour le traitement des acouphènes
US8993577B2 (en) 2009-02-20 2015-03-31 Astrazeneca Ab Cyclopropyl amide derivatives
WO2015144803A1 (fr) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Dérivés de quinoxaline utiles en tant que modulateurs de la kinase fgfr
US9249132B2 (en) 2010-12-16 2016-02-02 Nivalis Therapeutics, Inc. Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
US9290478B2 (en) 2010-11-29 2016-03-22 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9303030B2 (en) 2012-05-30 2016-04-05 Astex Therapeutics Limited Compounds
US9447098B2 (en) 2012-05-30 2016-09-20 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US9458133B2 (en) 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9493426B2 (en) 2013-04-26 2016-11-15 Astex Therapeutics Limited Quinazolinone derivatives useful as FGFR kinase modulators
WO2017050864A1 (fr) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Nouveaux composés
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
US10131634B2 (en) 2011-12-16 2018-11-20 Poseida Therapeutics, Inc. Method of treating pain
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10898482B2 (en) 2015-02-10 2021-01-26 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10961252B2 (en) 2016-06-27 2021-03-30 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012136148A (ru) 2010-02-18 2014-03-27 Астразенека Аб Новая кристаллическая форма производного циклопропилбензамида
TW201204727A (en) * 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN106632091B (zh) * 2015-10-29 2021-05-11 中国科学院上海药物研究所 喹唑啉化合物在调控神经干细胞增殖和分化中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590273A (en) * 1980-09-10 1986-05-20 Hoechst Aktiengesellschaft Isoquinoline compounds
WO2003066604A2 (fr) * 2002-02-05 2003-08-14 Novo Nordisk A/S Nouvelles aryl- et heteroarylpiperazines
WO2004080170A2 (fr) * 2003-03-10 2004-09-23 Basf Aktiengesellschaft Derives benzo(hetero)cycliques amino substitues
US20050070527A1 (en) * 2003-09-30 2005-03-31 Edwards James P. Quinoxaline compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590273A (en) * 1980-09-10 1986-05-20 Hoechst Aktiengesellschaft Isoquinoline compounds
WO2003066604A2 (fr) * 2002-02-05 2003-08-14 Novo Nordisk A/S Nouvelles aryl- et heteroarylpiperazines
WO2004080170A2 (fr) * 2003-03-10 2004-09-23 Basf Aktiengesellschaft Derives benzo(hetero)cycliques amino substitues
US20050070527A1 (en) * 2003-09-30 2005-03-31 Edwards James P. Quinoxaline compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAMPIANI ET AL: "Novel and Highly Potent 5-HT3 Receptor Agonists Based on a Pyrroloquinoxaline Structure" 1997, JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, PAGE(S) 3670-3678 , XP002137526 ISSN: 0022-2623 compound 11C *
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; JOSEPH-NATHAN, P. ET AL.: "Proton NMR study of some quipazine derivatives." XP002413308 Database accession no. 1990:54802 & SPECTROSCOPY, vol. 6, 1988, pages 249-257, *
DUKAT M ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS FOR THE BINDING OF ARYLPIPERAZINES AND ARYLBIGUANIDES AT 5-HT3 SEROTONIN RECEPTORS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 39, 1996, pages 4017-4026, XP001093858 ISSN: 0022-2623 *
HORI ET AL: "Novel 4-Phenoxy-2- (1-piperazinyl)quinazolines as Potent Anticonvulsive and Antihypoxic Agents" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 38, no. 3, March 1990 (1990-03), pages 681-687, XP002093298 ISSN: 0009-2363 *
LUMMA ET AL: JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 24, 1981, pages 93-101, XP002092960 ISSN: 0022-2623 *
MANABU HORI ET AL: "Novel 4-Substituted 2-Piperazinylquinazolines as potent Anticonvulsive and Antihypoxic Agents" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 38, no. 5, 1990, pages 1286-1291, XP002128282 ISSN: 0009-2363 *

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029381B2 (en) 2007-08-22 2015-05-12 Astrazeneca Ab Cyclopropyl amide derivatives
US8063215B2 (en) 2007-08-22 2011-11-22 Astrazeneca Ab Cyclopropyl amide derivatives
EP2077263A1 (fr) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines et composés hétérocycliques rélatifs et leur utilisation thérapeutique
WO2009134726A1 (fr) * 2008-04-28 2009-11-05 Abbott Laboratories Dérivés de pyrimidine substitués comme ligands des récepteurs à l’histamine h4
US8278311B2 (en) 2008-04-28 2012-10-02 Abbott Laboratories Substituted pyrimidine derivatives
US10195195B2 (en) 2008-12-24 2019-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
EP2201982A1 (fr) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur H4 de l'histamine pour le traitement de troubles vestibulaires
WO2010072829A1 (fr) 2008-12-24 2010-07-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes sélectifs du récepteur h4 de l'histamine dans le traitement de troubles vestibulaires
US9526725B2 (en) 2008-12-24 2016-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
US8993577B2 (en) 2009-02-20 2015-03-31 Astrazeneca Ab Cyclopropyl amide derivatives
US10676460B2 (en) 2009-09-03 2020-06-09 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US10214511B2 (en) 2009-09-03 2019-02-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9458114B2 (en) 2009-09-03 2016-10-04 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US9822096B2 (en) 2009-09-03 2017-11-21 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US8575184B2 (en) 2009-09-03 2013-11-05 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
US11008306B2 (en) 2009-09-03 2021-05-18 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
EP2545058A4 (fr) * 2010-03-10 2013-07-24 Kalypsys Inc Inhibiteurs hétérocycliques de récepteurs de l'histamine destinés au traitement de maladie
EP2545058A2 (fr) * 2010-03-10 2013-01-16 Kalypsys, Inc. Inhibiteurs hétérocycliques de récepteurs de l'histamine destinés au traitement de maladie
CN102869666A (zh) * 2010-03-10 2013-01-09 凯利普西斯公司 用于疾病治疗的组胺受体的杂环抑制剂
WO2011112766A2 (fr) 2010-03-10 2011-09-15 Kalypsys, Inc. Inhibiteurs hétérocycliques de récepteurs de l'histamine destinés au traitement de maladie
CN102869666B (zh) * 2010-03-10 2015-09-09 凯利普西斯公司 用于疾病治疗的组胺受体的杂环抑制剂
US8895601B2 (en) 2010-04-30 2014-11-25 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US9464071B2 (en) 2010-04-30 2016-10-11 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
WO2011135376A1 (fr) 2010-04-30 2011-11-03 Astex Therapeutics Limited Inhibiteurs de pyrazolyl-quinazoline kinase
EP3590934A1 (fr) 2010-04-30 2020-01-08 Astex Therapeutics Limited Inhibiteurs de kinase de quinoxaline pyrazolyle
US10519137B2 (en) 2010-04-30 2019-12-31 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US9850228B2 (en) 2010-04-30 2017-12-26 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US9290478B2 (en) 2010-11-29 2016-03-22 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9856236B2 (en) 2010-11-29 2018-01-02 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9249132B2 (en) 2010-12-16 2016-02-02 Nivalis Therapeutics, Inc. Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors
US10039759B2 (en) 2011-10-28 2018-08-07 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
US9309241B2 (en) 2011-10-28 2016-04-12 Astex Therapeutics Ltd Naphthyridine derivative compounds
WO2013061081A1 (fr) 2011-10-28 2013-05-02 Astex Therapeutics Limited Benzopyrazines anticancéreuses par le biais de l'inhibition de fgfr kinases
US9303029B2 (en) 2011-10-28 2016-04-05 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9309242B2 (en) 2011-10-28 2016-04-12 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
US9527844B2 (en) 2011-10-28 2016-12-27 Astex Therapeutics Limited Naphthyridine derivative compounds
WO2013061080A1 (fr) 2011-10-28 2013-05-02 Astex Therapeutics Limited Pyridopyrazines anti-cancéreuses par l'inhibition de kinases de fgfr
WO2013061074A1 (fr) 2011-10-28 2013-05-02 Astex Therapeutics Limited Quinolines comme modulateurs de la fgfr kinase
US10052320B2 (en) 2011-10-28 2018-08-21 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US9757364B2 (en) 2011-10-28 2017-09-12 Astex Therapeutics Ltd Naphthyridine derivative compounds
WO2013061077A1 (fr) 2011-10-28 2013-05-02 Astex Therapeutics Limited Nouveaux composés
US10045982B2 (en) 2011-10-28 2018-08-14 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
US9439896B2 (en) 2011-10-28 2016-09-13 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
US10131634B2 (en) 2011-12-16 2018-11-20 Poseida Therapeutics, Inc. Method of treating pain
US10272087B2 (en) 2012-05-30 2019-04-30 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US9447098B2 (en) 2012-05-30 2016-09-20 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US9737544B2 (en) 2012-05-30 2017-08-22 Astex Therapeutics Limited Compounds
US9303030B2 (en) 2012-05-30 2016-04-05 Astex Therapeutics Limited Compounds
US9688989B2 (en) 2012-06-08 2017-06-27 Sensorion H4 receptor inhibitors for treating tinnitus
WO2013182711A1 (fr) 2012-06-08 2013-12-12 Sensorion Inhibiteurs des récepteurs h4 pour le traitement des acouphènes
EP3378476A1 (fr) 2012-06-08 2018-09-26 Sensorion Inhibiteurs du récepteur h4 destinés au traitement des acouphènes
US9458133B2 (en) 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9493426B2 (en) 2013-04-26 2016-11-15 Astex Therapeutics Limited Quinazolinone derivatives useful as FGFR kinase modulators
US10421747B2 (en) 2014-03-26 2019-09-24 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
WO2015144803A1 (fr) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Dérivés de quinoxaline utiles en tant que modulateurs de la kinase fgfr
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
US10716787B2 (en) 2014-03-26 2020-07-21 Astex Therapeutics Ltd Combinations
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US11918576B2 (en) 2014-03-26 2024-03-05 Astex Therapeutics Ltd Combination of an FGFR inhibitor and a CMET inhibitor
US9902714B2 (en) 2014-03-26 2018-02-27 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
US11684620B2 (en) 2015-02-10 2023-06-27 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10898482B2 (en) 2015-02-10 2021-01-26 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017050864A1 (fr) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Nouveaux composés
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
US11248000B2 (en) 2016-06-27 2022-02-15 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
US10961252B2 (en) 2016-06-27 2021-03-30 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders

Also Published As

Publication number Publication date
CA2657702A1 (fr) 2008-01-10
JP2009541460A (ja) 2009-11-26
WO2008003702A3 (fr) 2008-04-10
EP2044027A2 (fr) 2009-04-08
AU2007271187A1 (en) 2008-01-10
US20100016293A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
EP2044027A2 (fr) Composés bicycliques fusionnés interagissant avec le récepteur histamine h4
EP2238119B1 (fr) Quinazolines et composés hétérocycliques relatifs et leur utilisation thérapeutique
EP1755606B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
ES2371383T3 (es) N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n&#39;-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
US20170224689A1 (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
JP2020516666A (ja) アポトーシス誘発剤
EP2270002A1 (fr) Dérivés de quinazoline comme inhibiteurs du H4-recepteur de l&#39;histamin dans le traitement de maladies inflammatoires
DE60036812T2 (de) Chinazolin derivate
KR20090107994A (ko) 퀴나졸리논 및 이소퀴놀리논 아세트아미드 유도체
TW201321377A (zh) 作為激酶抑制劑之胺基喹唑啉類
AU2013315396B2 (en) Prodrugs of amino quinazoline kinase inhibitor
JP6301374B2 (ja) キナーゼ阻害剤としてのキナゾリン類
RU2727194C2 (ru) Гетероциклические соединения для лечения заболевания
EP3847170B1 (fr) Nouveaux composés amidine cyclique pour le traitement d&#39;une maladie auto-immune
EP3587398A1 (fr) Nouveau ligand sélectif pour le récepteur dopaminergique d3, procédé de préparation correspondant et application pharmaceutique correspondante

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07787012

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2657702

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009517257

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007787012

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007271187

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007271187

Country of ref document: AU

Date of ref document: 20070703

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12307197

Country of ref document: US